ClinicalTrials.gg

Program

siplizumab

Also written as “MEDI-507”, “TCD601” and “Siplizumab”.

Its studies are mostly in Graft vs Host Disease · Psoriasis · Amyotrophic Lateral Sclerosis · Diabetes Mellitus, Type 1 · Kidney Diseases, led by 2 companies.

Furthest: phase 2, since Mar 12, 202017 company-led studies, 2 open or runningNext primary completion: Mar 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ITB-Med92 open or runningphase 2since Mar 12, 2020Mar 12, 2020Mar 28, 2028phase 2 · NCT07508787
AstraZeneca80 open or runningphase 2since Sep 13, 2005Mar 11, 2005none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2005First study: phase 1 study in LymphomaNew to AstraZenecaAstraZeneca · NCT00105313 · 80 enrolled · United States
  2. Jul 22, 2005Phase 1 study in Lymphoproliferative DisordersAstraZeneca · NCT00123942 · 31 enrolled · United States
  3. Sep 13, 2005Phase 2 study in PsoriasisAstraZeneca · NCT00192452 · 120 enrolled · United States
  4. Oct 4, 2007Phase 2 study in Plaque PsoriasisAstraZeneca · NCT00540618 · 420 enrolled · United States, Canada
  5. Dec 9, 20084 phase 1 studiesAstraZeneca · NCT00806208, NCT00807794, NCT00806728 and 1 more
  6. Mar 12, 2020ITB-Med's first study: phase 2 study in Kidney TransplantationNew to ITB-MedITB-Med · NCT04311632 · 13 enrolled · United States
  7. Mar 14, 20212 phase 2 studies in Kidney TransplantationITB-Med · NCT04803058, NCT04803006
  8. Dec 20, 2022Phase 2 study in Renal TransplantationITB-Med · NCT05669001 · 76 enrolled · United States
  9. Aug 25, 20232 phase 2 studiesITB-Med · NCT06025110, NCT06019507
  10. Apr 10, 2024Phase 2 study in Kidney TransplantationITB-Med · NCT06365437 · 33 enrolled · Austria, Spain, Sweden
  11. May 6, 2024Phase 1 study in Amyotrophic Lateral SclerosisITB-Med · NCT06453668 · 7 enrolled · Sweden
  12. Mar 11, 2026Phase 2 study in Rejection, PsychologyITB-Med · NCT07508787 · 120 planned · United States, Brazil, Spain

Ahead

  1. Mar 28, 2028Primary completion: phase 2 study in Rejection, PsychologyITB-Med · NCT07508787

TargetBeta

CD2 →read by rule
“T-cell surface antigen CD2 inhibitor”ChEMBL 37, by rule

Other programs on CD2

ProgramCompanyFurthest phaseStudies
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104ruleevolveimmune-united-incphase 11

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07508787Rejection, Psychology · United States, Brazil, Spain2RecruitingITB-MedMar 28, 2028120
NCT06453668Amyotrophic Lateral Sclerosis · Sweden1TerminatedITB-MedJul 2, 20267
NCT06365437Kidney Transplantation · Austria, Spain, Sweden2TerminatedITB-MedDec 11, 202433
NCT06025110Diabetes Mellitus, Type 1 · Belgium, Italy, Spain and more2TerminatedITB-MedJul 24, 20259
NCT06019507Liver Transplantation · Sweden2Active, not recruitingITB-MedJun 202612
NCT05669001Renal Transplantation · United States2CompletedITB-MedApr 10, 202676
NCT04803058Kidney Transplantation · United States, South Korea2TerminatedITB-MedFeb 17, 20267
NCT04803006Kidney Transplantation · United States2TerminatedITB-MedOct 30, 20254
NCT04311632Kidney Transplantation · United States2CompletedITB-MedOct 3, 202313
NCT00813618Graft vs Host Disease · United States1CompletedAstraZenecaJun 200410
NCT00807794Kidney Diseases · United States1CompletedAstraZenecaNov 199713
NCT00806728Neoplasms · United States1CompletedAstraZenecaNov 199817
NCT00806208Graft vs Host Disease · United States1CompletedAstraZenecaJan 200034
NCT00540618Plaque Psoriasis · United States, Canada2CompletedAstraZeneca420
NCT00192452Psoriasis · United States2CompletedAstraZeneca120
NCT00123942Lymphoproliferative Disorders · United States1TerminatedAstraZeneca31
NCT00105313Lymphoma · United States1TerminatedAstraZeneca80

How it is read

Names in the registry

  • “MEDI-507”, 20 entries
  • “TCD601”, 8 entries
  • “Siplizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.